Role of hypertension in kidney transplant recipients

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Cardiovascular events are a primary cause of mortality in kidney transplant recipients.
• Hypertension affects up to 90% of these patients, often remaining poorly controlled post-transplant.
• Abnormal blood pressure patterns, including masked and white-coat hypertension, are prevalent.

Purpose of the Study:

• To review the pathophysiology, diagnosis, prognostic significance, and management of hypertension in kidney transplant recipients.
• To highlight the complexity of blood pressure elevation in this population, including transplantation-specific factors.
• To address the under-researched nature of hypertension management in kidney transplantation.

Main Methods:

• Comprehensive review of existing data on hypertension in kidney transplant recipients.
• Analysis of pathophysiology, diagnostic challenges, and prognostic implications.
• Evaluation of current and potential management strategies, including lifestyle modifications and pharmacological options.

Main Results:

• Hypertension pathophysiology in kidney transplant recipients is multifactorial, involving both traditional and transplant-specific risks.
• Evidence for optimal management is limited, often extrapolated from general populations or small trials.
• Dihydropyridine calcium channel blockers are frequently used first-line agents due to renal safety, while other classes are underutilized.

Conclusions:

• Hypertension management in kidney transplant recipients is complex and requires further dedicated research.
• Lifestyle modifications are recommended as an initial management step.
• Optimal pharmacological approaches need clarification, balancing efficacy with renal and hemodynamic safety.